Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (66851) 66851
Conference Proceeding (262) 262
Book Chapter (78) 78
Magazine Article (45) 45
Dissertation (16) 16
Publication (15) 15
Book / eBook (7) 7
Newsletter (6) 6
Government Document (4) 4
Book Review (2) 2
Newspaper Article (2) 2
Paper (2) 2
Reference (2) 2
Web Resource (2) 2
Streaming Video (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
biological and medical sciences (60606) 60606
medical sciences (60598) 60598
hematologic and hematopoietic diseases (60289) 60289
leukemias. malignant lymphomas. malignant reticulosis. myelofibrosis (60099) 60099
humans (58400) 58400
science & technology (44944) 44944
life sciences & biomedicine (44740) 44740
male (32104) 32104
female (29822) 29822
middle aged (24387) 24387
hematology (22067) 22067
adult (21971) 21971
aged (19800) 19800
oncology (17606) 17606
abridged index medicus (13316) 13316
adolescent (9940) 9940
child (7918) 7918
prognosis (7757) 7757
aged, 80 and over (7325) 7325
tumors (6212) 6212
treatment outcome (5459) 5459
child, preschool (5423) 5423
animals (4746) 4746
antineoplastic combined chemotherapy protocols - therapeutic use (4712) 4712
retrospective studies (4191) 4191
leukemia (4118) 4118
pharmacology. drug treatments (4056) 4056
risk factors (3863) 3863
antineoplastic agents (3663) 3663
pathology (3647) 3647
infant (3524) 3524
bone marrow - pathology (3413) 3413
research (3295) 3295
mice (3261) 3261
karyotyping (3135) 3135
acute disease (3114) 3114
cancer (3112) 3112
translocation, genetic (3088) 3088
follow-up studies (3054) 3054
immunohistochemistry (3047) 3047
lymphoma (3023) 3023
chromosome aberrations (2964) 2964
diagnosis, differential (2844) 2844
chemotherapy (2826) 2826
care and treatment (2800) 2800
immunophenotyping (2789) 2789
survival analysis (2782) 2782
survival rate (2733) 2733
mutation (2720) 2720
tumor cells, cultured (2643) 2643
antineoplastic agents - therapeutic use (2613) 2613
dermatology (2583) 2583
polymerase chain reaction (2551) 2551
disease-free survival (2531) 2531
flow cytometry (2494) 2494
recurrence (2484) 2484
medicine & public health (2456) 2456
hemic and lymphatic diseases (2437) 2437
time factors (2413) 2413
remission induction (2406) 2406
immunopathology (2382) 2382
transplantation (2346) 2346
myelofibrosis (2329) 2329
young adult (2316) 2316
immunodeficiencies. immunoglobulinopathies (2296) 2296
health aspects (2278) 2278
lymphomas (2255) 2255
neoplasm staging (2236) 2236
leukemia, myeloid, acute - genetics (2229) 2229
immunoglobulinopathies (2175) 2175
combined modality therapy (2123) 2123
base sequence (2116) 2116
molecular sequence data (2023) 2023
cell line, tumor (2022) 2022
biopsy (2014) 2014
immunology (1949) 1949
genetic aspects (1915) 1915
apoptosis (1896) 1896
genetics & heredity (1850) 1850
primary myelofibrosis - pathology (1823) 1823
investigative techniques, diagnostic techniques (1748) 1748
analysis (1743) 1743
phenotype (1724) 1724
leukemia, myeloid, acute - pathology (1697) 1697
precursor cell lymphoblastic leukemia-lymphoma - genetics (1685) 1685
in situ hybridization, fluorescence (1680) 1680
lymphoma, non-hodgkin - pathology (1670) 1670
lymph nodes - pathology (1662) 1662
bone marrow (1651) 1651
disease progression (1651) 1651
pediatrics (1628) 1628
skin neoplasms - pathology (1625) 1625
reverse transcriptase polymerase chain reaction (1615) 1615
case-control studies (1602) 1602
gene expression (1592) 1592
hodgkin disease - pathology (1582) 1582
lymphoma - pathology (1558) 1558
general & internal medicine (1554) 1554
multiple myeloma (1521) 1521
diagnosis (1510) 1510
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (65888) 65888
German (342) 342
French (291) 291
Japanese (271) 271
Russian (148) 148
Italian (139) 139
Spanish (134) 134
Polish (66) 66
Chinese (60) 60
Czech (36) 36
Portuguese (33) 33
Hungarian (31) 31
Korean (24) 24
Dutch (23) 23
Romanian (22) 22
Turkish (21) 21
Danish (12) 12
Swedish (11) 11
Norwegian (6) 6
Serbian (5) 5
Slovak (5) 5
Bulgarian (4) 4
Croatian (4) 4
Hebrew (4) 4
Finnish (3) 3
Ukrainian (2) 2
Afrikaans (1) 1
Bosnian (1) 1
Latin (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
by Naseema Gangat and Domenica Caramazza and Rakhee Vaidya and Geeta George and Kebede Begna and Susan Schwager and Daniel Van Dyke and Curtis Hanson and Wenting Wu and Animesh Pardanani and Francisco Cervantes and Francesco Passamonti and Ayalew Tefferi
Journal of clinical oncology, ISSN 0732-183X, 02/2011, Volume 29, Issue 4, pp. 392 - 397
Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Blood Transfusion - mortality | Primary Myelofibrosis - mortality | Predictive Value of Tests | Leukemia - blood | Prognosis | Age Factors | Health Status Indicators | Humans | Middle Aged | Male | Primary Myelofibrosis - blood | Young Adult | Time Factors | Cell Transformation, Neoplastic - genetics | Karyotyping | Aged, 80 and over | Adult | Female | Leukocyte Count | Leukemia - genetics | Severity of Illness Index | Primary Myelofibrosis - diagnosis | Reproducibility of Results | Risk Assessment | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Leukemia - therapy | Chi-Square Distribution | Bone Marrow Examination | Databases as Topic | Disease-Free Survival | Primary Myelofibrosis - genetics | Platelet Count | Adolescent | Leukemia - diagnosis | Aged | Primary Myelofibrosis - therapy | Hemoglobins - analysis | Leukemia - mortality | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
by Passamonti, Francesco and Cervantes, Francisco and Vannucchi, Alessandro Maria and Morra, Enrica and Rumi, Elisa and Pereira, Arturo and Guglielmelli, Paola and Pungolino, Ester and Caramella, Marianna and Maffioli, Margherita and Pascutto, Cristiana and Lazzarino, Mario and Cazzola, Mario and Tefferi, Ayalew
Blood, ISSN 0006-4971, 03/2010, Volume 115, Issue 9, pp. 1703 - 1708
Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Primary Myelofibrosis - mortality | Prognosis | Age Factors | Humans | Middle Aged | Risk Factors | Proportional Hazards Models | Hemoglobins - metabolism | Male | Models, Statistical | Primary Myelofibrosis - blood | Models, Biological | Female | Aged | Leukocyte Count | Primary Myelofibrosis - therapy | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text What is pre‐fibrotic myelofibrosis and how should it be managed in 2018?
by Curto‐Garcia, Natalia and Ianotto, Jean‐Christophe and Harrison, Claire N
British journal of haematology, ISSN 0007-1048, 10/2018, Volume 183, Issue 1, pp. 23 - 34
primary myelofibrosis | myeloproliferative neoplasm | classification | management | prefibrotic myelofibrosis | Life Sciences & Biomedicine | Hematology | Science & Technology | Primary Myelofibrosis - diagnosis | Prognosis | World Health Organization | Humans | Myeloproliferative Disorders - classification | Fibrosis | Primary Myelofibrosis - classification | Disease Management | Primary Myelofibrosis - therapy | Primary Myelofibrosis - pathology | Myelofibrosis | Young adults | Leukemia | Lactate dehydrogenase | Management | Patients | Neoplasms | L-Lactate dehydrogenase | Medical prognosis | Classification | Bone marrow | Thrombocytosis | Adults | Diagnostic systems | Lactic acid | Diagnosis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
by Verstovsek, Srdan and Mesa, Ruben A and Gotlib, Jason and Levy, Richard S and Gupta, Vikas and DiPersio, John F and Catalano, John V and Deininger, Michael and Miller, Carole and Silver, Richard T and Talpaz, Moshe and Winton, Elliott F and Harvey, Jimmie H and Arcasoy, Murat O and Hexner, Elizabeth and Lyons, Roger M and Paquette, Ronald and Raza, Azra and Vaddi, Kris and Erickson-Viitanen, Susan and Koumenis, Iphigenia L and Sun, William and Sandor, Victor and Kantarjian, Hagop M
The New England journal of medicine, ISSN 0028-4793, 03/2012, Volume 366, Issue 9, pp. 799 - 807
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | Primary Myelofibrosis - mortality | Pyrazoles - therapeutic use | Splenomegaly - drug therapy | Follow-Up Studies | Humans | Middle Aged | Male | Spleen - drug effects | Primary Myelofibrosis - pathology | Protein Kinase Inhibitors - adverse effects | Aged, 80 and over | Adult | Female | Spleen - pathology | Janus Kinase 2 - antagonists & inhibitors | Pyrazoles - adverse effects | Primary Myelofibrosis - drug therapy | Double-Blind Method | Kaplan-Meier Estimate | Organ Size | Janus Kinase 1 - antagonists & inhibitors | Leukemia, Myeloid, Acute - mortality | Cell Transformation, Neoplastic | Protein Kinase Inhibitors - therapeutic use | Intention to Treat Analysis | Quality of Life | Aged | Drugs | Dose-response relationship (Biochemistry) | Product/Service Evaluations | Myelofibrosis | Drug therapy | Spleen | Thrombocytopenia | Medical research | Transformation | Cytokines | Anemia | Myeloid leukemia | Medical treatment | Clinical trials | Kinases | Survival | Patients | Magnetic resonance imaging | Blood platelets | Janus kinase | Acute myeloid leukemia | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
by Harrison, Claire and Kiladjian, Jean-Jacques and Al-Ali, Haifa Kathrin and Gisslinger, Heinz and Waltzman, Roger and Stalbovskaya, Viktoriya and McQuitty, Mari and Hunter, Deborah S and Levy, Richard and Knoops, Laurent and Cervantes, Francisco and Vannucchi, Alessandro M and Barbui, Tiziano and Barosi, Giovanni
The New England journal of medicine, ISSN 0028-4793, 03/2012, Volume 366, Issue 9, pp. 787 - 798
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | Primary Myelofibrosis - mortality | Primary Myelofibrosis - drug therapy | Pyrazoles - therapeutic use | Splenomegaly - drug therapy | Follow-Up Studies | Humans | Middle Aged | Organ Size | Male | Spleen - drug effects | Primary Myelofibrosis - pathology | Protein Kinase Inhibitors - adverse effects | Janus Kinase 1 - antagonists & inhibitors | Cause of Death | Protein Kinase Inhibitors - therapeutic use | Survival Analysis | Aged, 80 and over | Quality of Life | Adult | Female | Aged | Spleen - pathology | Janus Kinase 2 - antagonists & inhibitors | Pyrazoles - adverse effects | Drugs | Enzyme inhibitors | Myelofibrosis | Dosage and administration | Product/Service Evaluations | Drug therapy | Comparative analysis | Spleen | Thrombocytopenia | Splenomegaly | Anemia | Myeloid leukemia | Medical treatment | Polycythemia vera | Patients | Quality of life | Signal transduction | Magnetic resonance imaging | Computed tomography | Polycythemia | Janus kinase | Mutation | Acute myeloid leukemia | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT)
by Mesa, Ruben A and Verstovsek, Srdan and Cervantes, Francisco and Barosi, Giovanni and Reilly, John T and Dupriez, Brigitte and Levine, Ross and Le Bousse-Kerdiles, Marie-Caroline and Wadleigh, Martha and Campbell, Peter J and Silver, Richard T and Vannucchi, Alessandro M and Deeg, H. Joachim and Gisslinger, Heinz and Thomas, Deborah and Odenike, Olatoyosi and Solberg, Lawrence A and Gotlib, Jason and Hexner, Elizabeth and Nimer, Stephen D and Kantarjian, Hagop and Orazi, Attilio and Vardiman, James W and Thiele, Juergen and Tefferi, Ayalew and On behalf of the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) and International Working Group for Myelofibrosis Research and Treatment (IWG-MRT)
Leukemia research, ISSN 0145-2126, 2007, Volume 31, Issue 6, pp. 737 - 740
Hematology, Oncology and Palliative Medicine | IWG-MRT | Primary myelofibrosis | Myelofibrosis | Myelofibrosis with myeloid metaplasia | Chronic idiopathic myelofibrosis | International Working Group for Myelofibrosis Research and Treatment | Myeloproliferative disorders | Blast Crisis - classification | Blast Crisis - pathology | Thrombocythemia, Essential - classification | Humans | Polycythemia Vera - classification | Terminology as Topic | Primary Myelofibrosis - classification | Thrombocythemia, Essential - pathology | Primary Myelofibrosis - pathology | Cell Transformation, Neoplastic - classification | Polycythemia Vera - pathology | Cell Transformation, Neoplastic - pathology | Chronic Disease | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
by Verstovsek, Srdan and Kantarjian, Hagop and Mesa, Ruben A and Pardanani, Animesh D and Cortes-Franco, Jorge and Thomas, Deborah A and Estrov, Zeev and Fridman, Jordan S and Bradley, Edward C and Erickson-Viitanen, Susan and Vaddi, Kris and Levy, Richard and Tefferi, Ayalew
The New England journal of medicine, ISSN 0028-4793, 09/2010, Volume 363, Issue 12, pp. 1117 - 1127
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | Humans | Middle Aged | Male | Spleen - drug effects | Dose-Response Relationship, Drug | Primary Myelofibrosis - blood | Anemia - drug therapy | Aged, 80 and over | Adult | Female | Spleen - pathology | Anemia - etiology | Janus Kinase 2 - antagonists & inhibitors | STAT3 Transcription Factor - metabolism | Cytokines - blood | Pyrazoles - adverse effects | Primary Myelofibrosis - drug therapy | Hepatomegaly - drug therapy | Primary Myelofibrosis - complications | Janus Kinase 2 - genetics | Biomarkers - blood | Janus Kinase 1 - antagonists & inhibitors | Primary Myelofibrosis - genetics | Pyrazoles - administration & dosage | STAT3 Transcription Factor - drug effects | Aged | Mutation | Hepatomegaly - etiology | Disease | Patients | Medical treatment | Risk factors | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis
by Masarova, Lucia and Bose, Prithviraj and Daver, Naval and Pemmaraju, Naveen and Newberry, Kate J and Manshouri, Taghi and Cortes, Jorge and Kantarjian, Hagop M and Verstovsek, Srdan
Leukemia research, ISSN 0145-2126, 2017, Volume 59, pp. 110 - 116
Hematology, Oncology and Palliative Medicine | polycythemia vera myelofibrosis | essential thrombocythemia myelofibrosis | Primary myelofibrosis | Prognosis | Post | Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Primary Myelofibrosis - mortality | Follow-Up Studies | Leukemia, Myeloid, Acute - pathology | Humans | Middle Aged | Male | Survival Rate | Thrombocythemia, Essential - pathology | Primary Myelofibrosis - pathology | Disease Progression | Young Adult | Aged, 80 and over | Adult | Female | Aged | Polycythemia Vera - pathology | Pets | Anemia | Polycythemia | Leukemia | Index Medicus | post-essential thrombocythemia myelofibrosis | post-polycythemia vera myelofibrosis | primary myelofibrosis | prognosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Gli1+ Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target
by Schneider, Rebekka K and Mullally, Ann and Dugourd, Aurelien and Peisker, Fabian and Hoogenboezem, Remco and Van Strien, Paulina M.H and Bindels, Eric M and Heckl, Dirk and Büsche, Guntram and Fleck, David and Müller-Newen, Gerhard and Wongboonsin, Janewit and Ventura Ferreira, Monica and Puelles, Victor G and Saez-Rodriguez, Julio and Ebert, Benjamin L and Humphreys, Benjamin D and Kramann, Rafael
Cell stem cell, ISSN 1934-5909, 06/2017, Volume 20, Issue 6, pp. 785 - 800.e8
myeloproliferative neoplasms | myelofibrosis | Gli1 | bone marrow fibrosis | mesenchymal stem cells | Cell & Tissue Engineering | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Myofibroblasts - pathology | Primary Myelofibrosis - drug therapy | Zinc Finger Protein GLI1 - metabolism | Zinc Finger Protein GLI1 - genetics | Humans | Mice, Transgenic | Primary Myelofibrosis - pathology | Pyrimidines - pharmacology | Mesenchymal Stem Cells - pathology | Myofibroblasts - metabolism | Cell Differentiation - genetics | Primary Myelofibrosis - genetics | Animals | Cell Differentiation - drug effects | Zinc Finger Protein GLI1 - antagonists & inhibitors | Cell Proliferation - drug effects | Mice | Pyridines - pharmacology | Mesenchymal Stem Cells - metabolism | Primary Myelofibrosis - metabolism | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
by Ayalew Tefferi and Rakhee Vaidya and Domenica Caramazza and Christy Finke and Terra Lasho and Animesh Pardanani
Journal of clinical oncology, ISSN 0732-183X, 04/2011, Volume 29, Issue 10, pp. 1356 - 1363
Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Predictive Value of Tests | Up-Regulation | Prognosis | Humans | Middle Aged | Male | Primary Myelofibrosis - pathology | Case-Control Studies | Protein Array Analysis - methods | Primary Myelofibrosis - blood | Interleukin-12 - blood | Aged, 80 and over | Adult | Female | Cytogenetic Analysis | Interleukin-8 - blood | Enzyme-Linked Immunosorbent Assay | Risk Assessment | Primary Myelofibrosis - immunology | Receptors, Interleukin-2 - blood | Risk Factors | Janus Kinase 2 - genetics | Kaplan-Meier Estimate | Proportional Hazards Models | Genotype | Interleukin-15 - blood | Minnesota | Chi-Square Distribution | Bone Marrow Examination | Biomarkers, Tumor - blood | Phenotype | Primary Myelofibrosis - genetics | Biopsy | Aged | Mutation | Biometrics | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights